Abbott: Mt. Everest Heroes Summit a Positive Life

Innovations in science-based nutrition help Sherpas maintain their weight and strength.

Abbott is No. 10 on the DiversityInc Top 50 Companies list


(Originally published on Abbott.com)

Swirling snow. Freezing temperatures. Hidden crevasses.

Only the world's most elite climbers are crazy enough to seek these hazards.

To conquer the elements and scale the 29,029 feet above sea level, most mountaineers rely on true experts to lead the way up Mount Everest: Sherpas.

They spend their lives guiding climbers to the top. Doing so takes a toll on their bodies.

A truly demanding job

Sherpas — sure-footed Nepalese mountaineers — are the invaluable guides to thrill-seeking climbers itching to reach Everest's summit. They trek through extreme elements while carrying packs that weigh about 22 pounds.

The perils of the mountain itself are infamous. The dangers faced by Sherpas back at base camp are less well-known.

As they climb, Sherpas burn thousands of calories and the ensuing altitude sickness often results in nutritional deficiencies. Sherpas lose on average 19 to 22 pounds every time up.

Achieving health and strength

Sherpas need to replenish their bodies with essential nutrients during expeditions. Abbott's nutrition team in India saw the problem and wanted to help.

Dr. Sandeep Raj Kunwar from Kathmandu established a health checkup camp and created nutrition plans that included Abbott's Ensure science-based nutritional drinks. "This helped give the Sherpas the required strength and energy to withstand the demanding conditions during the summit," said Debotpal Sengupta of Abbott's nutrition business in India.

At the health checkup camp, the Sherpas received medical examinations, watched an informational video on Ensure nutritional drinks, and were given a diet chart that showed them how to meet daily nutritional needs.

"We were exhausted and disoriented trekking from camp 1 to camp 3," Mingma Sherpa, a seasoned guide, said. "Then we mixed Ensure in mineral water and drank it. We felt good and strong when we resumed climbing."

Mingma said the Sherpas are now better able to maintain their weight and strength. "No other company has ever thought about our health and how to help stop our weight loss," Mingma said. "Abbott has given us that."

Learn about career opportunities at Abbott

Abbott: Connected Devices Turn Data Into Better Health

Abbott's Robert Ford Joins a Panel Discussing the Potential for Connected Medical Devices to Improve Patient Care and Drive Better Outcomes.

Originally Published by Abbott.

Today's medical devices are creating terabytes of information that gives patients, doctors and health providers real-time insight into someone's vital statistics, heart health and even bloodwork.

But can all this new information really make someone healthier?

Read More Show Less

Abbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management

State-of-the-art multi-assay test system helps people with diabetes get the HbA1c results they need within three minutes — allowing more time for consultation and care during a single healthcare visit.

Originally Published by Abbott.

Abbott announced the launch of its Afinion™ 2 analyzer in the U.S., the newest generation of the Afinion test system. The Afinion 2 builds on Abbott's heritage in diabetes care by empowering patients with information about their health that they can discuss with their providers during a single visit.

Read More Show Less

Abbott's Xience Sierra Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan.

Originally Published by Abbott.

Abbott announced that Japan's Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra™, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent. XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases.

XIENCE Sierra was designed to help doctors more easily treat people with difficult-to-treat blockages that involve multiple or totally blocked arteries or complications such as diabetes. Complex cases are increasingly prevalent as people with coronary artery disease are living longer.

"Extensive clinical data and 10 years of real-world experience with the XIENCE family of stents provide doctors with confidence that they are treating their patients with one of the safest stents available," said Chuck Brynelsen, senior vice president of Abbott's vascular business. "National reimbursement of XIENCE Sierra will provide people in Japan with greater access to this life-changing technology that can help them live their best lives."

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan. National reimbursement in Japan will enable doctors to treat more patients with XIENCE Sierra through the country's health insurance plans. XIENCE Sierra was approved in Japan on April 4, 2018, received CE Mark in Europe late last year, and is under review with the U.S. Food and Drug Administration.

XIENCE has been studied in over 100 clinical trials and in 10 years of global real-world experience. Its safety profile is unprecedented with consistent low rates of stent thrombosis, even in complex cases. More than eight million people worldwide have received a XIENCE stent since its initial regulatory approval.